Announcements
04/03/2014
This hearing will address China’s recent healthcare reforms, market access for U.S. medical goods and services in China, and the safety of medical products imported from China into the United States. China is growing more affluent and urbanized, and is also facing new healthcare challenges. The Chinese government has launched ambitious reforms to expand coverage and improve care. This hearing will consider whether U.S. drug and medical device makers are able to compete in China’s market. It will also assess the U.S. Food and Drug Administration’s ongoing efforts to regulate drugs and drug ingredients imported from China into the United States.
04/01/2014
This paper provides an overview and assess key points of China’s 2014 Government Work Report’s plans for financial system liberalization, fiscal reform, administrative reform, environmental regulation, urbanization and rural land reform, and healthcare reform.
03/27/2014
The U.S. trade deficit with China continues to grow but at a slower rate. A key reason for this is the boom in U.S. automotive and aerospace shipments to China. As China becomes more affluent and urbanized, ordinary Chinese are driving more cars and traveling more by frequently by air. China’s future demand, however, could be affected by pollution, traffic bottlenecks, and other factors. U.S. companies must also contend with China’s industrial policy, which tilts the playing field toward domestic industry. In the long run, technology transfer and off-shoring could erode U.S. competitiveness and take business away from U.S. plants.
03/26/2014
This hearing will address China’s recent healthcare reforms, market access for U.S. medical goods and services in China, and the safety of medical products imported from China into the United States. China is growing more affluent and urbanized, and is also facing new healthcare challenges. The Chinese government has launched ambitious reforms to expand coverage and improve care. This hearing will consider whether U.S. drug and medical device makers are able to compete in China’s market. It will also assess the U.S. Food and Drug Administration’s ongoing efforts to regulate drugs and drug ingredients imported from China into the United States.
03/22/2014
Revised March 22, 2014.
After the publication of this report on September 5, 2013, Microsoft brought to the authors’ attention new information about its partnership with Chinese company 21Vianet. The original version of the report inaccurately characterized certain aspects of the Microsoft-21Vianet partnership. A revised discussion of this partnership is provided on pages 32-34. The authors would like to thank Microsoft for their assistance in clarifying the details of 21Vianet’s Windows Azure service.
03/21/2014
This paper looks at China's foreign exchange reserves and holdings of U.S. Treasuries, and examines China’s efforts to diversify its investments
